TABLE 4.
Kaplan–Meier analysis of 5‐year OS (%) among 629 cT4b tumors undergoing definitive treatment.
| Surgical resection + additional therapy | RT/CRT | p‐value | |
|---|---|---|---|
| Overall | 57.1 | 39.4 | .006 |
| Histology | |||
| Adenocarcinoma | 56.8 | 16.1 | .002 |
| Adenoid cystic carcinoma | 70.1 | 29.8 | <.001 |
| Neuroendocrine carcinoma | 58.1 | 68.8 | .949 |
| Mucoepidermoid carcinoma | 25.0 | 50.0 | .960 |
| Melanoma | 34.9 | 50.0 | .231 |
| Esthesioneuroblastoma | 80.8 | 69.2 | .479 |
| Undifferentiated carcinoma | 43.3 | 55.6 | .414 |
| Primary site | |||
| Nasal cavity | 61.5 | 40.6 | .079 |
| Maxillary sinus | 57.6 | 35.0 | .148 |
| Ethmoid sinus | 51.6 | 42.3 | .337 |
| Frontal sinus | 54.5 | ‐ | ‐ |
| Sphenoid sinus | 71.4 | 9.1 | .004 |
| Sinus: overlapping, unspecified | 48.0 | 33.3 | .849 |
| Nasopharynx | 88.9 | 58.8 | .417 |
| Clinical nodal metastasis | |||
| No | 40.7 | 88.9 | .015 |
| Yes | 57.4 | 40.6 | .130 |
Abbreviations: CRT, chemoradiotherapy; OS, overall survival; RT, radiotherapy. Bolded values indicate statistically significant results (p<0.05)